NEW YORK (GenomeWeb) — Chinese startup Cure Genetics announced today that it has raised $17 million in a Series A financing round. The round was led by Qiming Venture Partners and included investments from CTS Capital and Ascendin Investment.
China-based Cure Genetics has raised $17m in series A funding, led by Qiming Venture Partners, with investment from CTS Capital and Ascendin Investment. The company is developing a drug that targets the gene for an inherited form of muscular dystrophy (MD).